Lantern Pharma/$LTRN
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Lantern Pharma
Lantern Pharma Inc is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Its proprietary AI and machine learning (ML) platform, RADR, uses oncology-focused data points and advanced ML algorithms to solve billion-dollar, real-world problems in cancer drug development. The group's growing pipeline of precision therapies has been accelerated using AI and input from world-class scientific advisors and collaborators.
Ticker
$LTRN
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
24
ISIN
US51654W1018
Website
Lantern Pharma Metrics
BasicAdvanced
$35M
-
-$1.85
1.54
-
Price and volume
Market cap
$35M
Beta
1.54
52-week high
$4.46
52-week low
$2.55
Average daily volume
64K
Financial strength
Current ratio
4.858
Quick ratio
4.601
Long term debt to equity
0.199
Total debt to equity
1.162
Management effectiveness
Return on assets (TTM)
-43.68%
Return on equity (TTM)
-75.66%
Valuation
Price to book
2.08
Price to tangible book (TTM)
2.08
Price to free cash flow (TTM)
-1.819
Growth
Earnings per share change (TTM)
13.79%
3-year earnings per share growth (CAGR)
13.45%
Lantern Pharma News
AllArticlesVideos
Lantern Pharma's LP-184 Shows Promising In Vivo Activity in Atypical Teratoid Rhabdoid Tumors (ATRT) at SNO Pediatric Conference, Further Validating Rare Pediatric Disease Designation and Pathway to Clinical Trials
Business Wire·2 weeks ago
Lantern Pharma Reports First Quarter 2025 Financial Results and Business Updates
Business Wire·4 weeks ago
Lantern Pharma Secures FDA Clearance for Planned Phase 1b/2 Trial of LP-184 in Biomarker-Defined, Treatment-Resistant NSCLC Patients with High Unmet Clinical Need
Business Wire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Lantern Pharma stock?
Lantern Pharma (LTRN) has a market cap of $35M as of June 13, 2025.
What is the P/E ratio for Lantern Pharma stock?
The price to earnings (P/E) ratio for Lantern Pharma (LTRN) stock is 0 as of June 13, 2025.
Does Lantern Pharma stock pay dividends?
No, Lantern Pharma (LTRN) stock does not pay dividends to its shareholders as of June 13, 2025.
When is the next Lantern Pharma dividend payment date?
Lantern Pharma (LTRN) stock does not pay dividends to its shareholders.
What is the beta indicator for Lantern Pharma?
Lantern Pharma (LTRN) has a beta rating of 1.54. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.